electroCore, Inc. (ECOR)

[Polyphemus]

Your question is on target, especially after a few quarters of commercialization (now March 2019). There has been news releases about insurance coverage, experience with free prescriptions, new executives, and hints at a rheumatology indication. We've had little information about unit sales in any geographic market or net average sales price. When will we get some important hard data that validates the strategic decisions by management to pursue the headache program (vs. alternative targets)?

Various electrical and other types of stimulators have developed traction in orthopaedics and some sectors of pain control, though adoption has generally been slow. These treatments are often relegated to patient populations who have been nonresponsive to all other prior treatments and therapies. Patient compliance with external stimulators has always been an issue, especially for treatment of chronic conditions. There may be a position for this device approach for this indication, not clear about its size or profitability.